Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...

Tesla's new car sales in Britain rose year-on-year in June amid a broader recovery in the electric-vehicle market, data ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The UK’s new car market grew for the second consecutive month in June, as registrations rose 6.7% to 191,316 units, according ...

UK vehicle production continues to face constraints, with figures from the Society of Motor Manufacturers and Traders (SMMT) ...